Horizon Discovery Group plc signs Master Services Agreement for approximately $1.2 million
25 September 2014 | By Horizon Discovery
Agreement covers development of molecular reference standards for companion diagnostics...
List view / Grid view
25 September 2014 | By Horizon Discovery
Agreement covers development of molecular reference standards for companion diagnostics...
25 September 2014 | By Probiodrug
Probiodrug AG announces its intention to raise new funds through an Initial Public Offering and listing on Euronext Amsterdam...
23 September 2014 | By nLife
The funding will help characterize the mechanism of action of nLife’s lead compound NLF-PD-1233 in a Parkinson disease model and find a proper dose to engage clinical development...
23 September 2014 | By The Institute of Cancer Research
Even long stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports...
23 September 2014 | By Horizon Discovery
Horizon Discovery Group plc announces its interim results for the six months ended 30 June 2014...
22 September 2014 | By Children’s Cancer Institute and Abcam plc
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development...
19 September 2014 | By Sanofi
Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease...
19 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, jointly announce an exclusive global license and development collaboration...
16 September 2014 | By Andrew Lloyd & Associates
Curie-Cancer and Inventiva announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR...
15 September 2014 | By The Institute of Cancer Research, London
Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease...
12 September 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces the appointment of Professor Roberto Pellicciari to the Company’s Scientific Advisory Board and as a consultant to the Company...
11 September 2014 | By Oxford Global Conferences
Oxford Global Conferences are proud to present the Drug Discovery USA Congress, taking place on 21 – 22 October at the Hyatt Boston Harbor Hotel, Boston, USA...
11 September 2014 | By Waters
Waters Corporation (NYSE: WAT) today celebrated the official opening of its new, custom-built mass spectrometry headquarters in Wilmslow, UK, confirming the company's commitment to innovation and the expanded usage of mass spectrometry...
11 September 2014 | By Ario Pharma
New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates...
11 September 2014 | By DPT Laboratories
DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, announces the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities...